



Co-Lab
AccelBio

COLLABORATIVE
LABORATORY
TO FOSTER
TRANSLATION
AND
DRUG DISCOVERY

1

CoLAB status is granted by the Portuguese FCT for a period of **5 years**, renewable, after an evaluation process by an international panel of experts (since 2017).

2

CoLABs have by creation requirement an autonomous and legal status, either a **non-profit association** or a **private company**, and a mix of partners involving research units, knowledge transfer entities and private companies.


3

One central piece in the application is a **5-year business plan**, as following the initial launching and seed funding stage, the CoLAB will rely on a triangle of **state funding**, **competitive funding**, and **services and products delivered to the market**.

Profit is not a goal as all money generated is invested back in R&I.

CoLab AccelBio: From Creation to Operations

exCell the patient mission



AccelBio is a **Collaborative Laboratory (CoLAB)** with a distinct mission: to facilitate and accelerate the **translation, commercialization,** and global **dissemination of cutting-edge biomedical discoveries and innovations** originating from research and development centres in Portugal.

AccelBio leverages and complements the combined existing drug discovery capacities of all associate members, ranging from target validation to preclinical studies.

Working
collaboratively
with researchers

Our Associates comprise Academic, Pharma
and Biotech companies, a Biotechnology Park
and a Venture partner

GIMM



Gulbenkian
Institute for
Molecular
Medicine



TÉCNICO LISBOA



UNIVERSIDADE DE
COIMBRA



BSIM
THERAPEUTICS



TARGETEX
TARGETED THERAPEUTICS



basinnov
life sciences*

**VERTICAL
SENTINEL**




biocant park



Biovance
Capital

AIM: AVOID LOSS IN TRANSLATION



EXPERTISE

exCell the patient mission

Enable discoveries to progress into assets

Target
validation

Hit ID

Lead
optimization

Early ADMET

Business development

We make use of the decentralized laboratories of the Associate Members. This integrated network capitalizes on complementary skills, fostering a collaborative environment.

In Silico

- Molecular dynamics
- Drug Design
- Ligand-based and Structure-based drug discovery
- Pharmacophore modeling
- Binding affinity calculations
- Selectivity predictions

Pharmacology

- Molecular imaging
- ADME/TOX
- In vivo models
- Organoids

Therapeutic modalities

- Antibody discovery and development
- Small molecules

Screening


- Chemical Libraries
- RNAi, siRNA & CRISPR screening

Chemistry

- MedChem
- Mass Spec

Biology

- Transcriptomics
- Proteomics
- Metabolomics
- Advanced in vitro models
- Human samples



Enable discoveries to progress into drug assets		Business model
Target validation	Hit ID	<ul style="list-style-type: none">- Co-development agreements- R&D partnerships- Licensing agreements of our assets- Building a company around an asset(s), including raising capital, tech transfer and business development activities- Fee for services
Lead optimization	Early ADMET	

MULTIDISCIPLINARY TEAM

exCell the patient mission



Bárbara Gomes
CEO



Silvia Almeida
CSO



Ricardo Viais
Project Manager



João Leandro
Translational R&D -
Drug Discovery



Vânia Cardoso
Translational R&D -
Drug Discovery



Bruno L. Victor
Computational
Medicinal Chemist



Caio Franco
R&D - HTS



Jacek Marzec
R&D - Bioinformatics



Margarida Coelho
R&D - Proteomics and
Metabolomics



Mariana Branco
R&D - Advanced
in-vitro systems



Cláudia Miranda
R&D - Advanced
in-vitro systems



Ana Luísa Rayagra
Technician - Advanced
in-vitro systems

CoLab AccelBio - mission and goals

exCell the patient mission

Guide and support the transformation of innovative scientific insights into successful drug discovery programs that can deliver assets: novel therapeutics

1

Acceleration of drug discovery projects

Identify and translate drug targets into drug discovery programs and new drugs



Pipelines: CNS (Alzheimer's, Epilepsy),
Immunology (T-cell activation),
Oncology (Gastric Cancer), Obesity

+ Annual Open Call & New partnerships

include experimental & business development support

2

R&I agenda in key emerging technology platforms

Develop unique platforms to support multiple drug discovery programs



Multimomics
(transcriptomics, proteomics, metabolomics)
Computational Chemistry
HTS
Organoids (kidney, heart, brain)

3

Training programs


Educate the next generation of sciencepreneurs to lead new companies



Webinars,
Interaction with partners and society,
Design of academic programs

Acceleration of drug discovery projects

exCell the patient mission



Product centric approach based
on industry and regulatory
standards


Quality-like System

Valorisation plan:

Target Product Profile

Milestones/end points & go/no-go
decisions


Acceleration of drug discovery projects



Acceleration of drug discovery projects- Securing Competitive Funding


exCell the patient mission

Testimonial of AccelBio's added value



“An added value is represented by partnership with AccelBio.”


Acceleration of drug discovery projects- Quality-like System



- 13 SOPs approved
- 12 SP designed
- 9 SR written
- 9 events reported and investigated
- Samples
- Reagents
- Consumables

Acceleration of drug discovery projects-

OPEN CALL



New drug assets with capacity to generate new IP

Two projects selected to be supported by AccelBio

€50K over 18 months

Expert guidance and a network of resources



1

Acceleration of drug discovery projects

Identify and translate drug targets into drug discovery programs and new drugs



Pipelines: CNS (Alzheimer's, Epilepsy),
Immunology (T-cell activation),
Oncology (Gastric Cancer), Obesity

+ Annual Open Call & New partnerships

include experimental & business development support



2

R&I agenda in key emerging technology platforms

Develop unique platforms to support multiple drug discovery programs



Multomics

(transcriptomics, proteomics, metabolomics)

Computational Chemistry & HTS

Organoids (kidney, heart, brain)



3

Training programs

Educate the next generation of sciencenpreneurs to lead new companies

R&I agenda in key emerging technology platforms

Organoids

Drug discovery and development: test candidate efficacy and mechanism of action

Safety and toxicity studies: evaluate safety and toxicity profiles using healthy models

Brain
Cardiac
Kidney

Personalized medicine: develop organoids from patient cells to design targeted and personalized therapies and stratify your patient population

Bridging *in vitro* and *in vivo*: Identify your target patient population before entering the clinical trial

Predictive biomarker identification: determine potential biomarkers of therapeutic response with companion diagnostics

Multomics & Computational Chemistry

- From transcriptomics to proteomics and metabolomics, integrated with bioinformatics
- Computational Chemistry: Molecular Profiling, Dynamics, and Docking, Predictive ML and AI models
- **Enabling discovery and validation of new targets and identification and optimization of new hits**

Antibody drug conjugates

- New linkers



1

Acceleration of drug discovery projects

Identify and translate drug targets into drug discovery programs and new drugs



Pipelines: CNS (Alzheimer's, Epilepsy),
Immunology (T-cell activation),
Oncology (Gastric Cancer), Obesity

+ Annual Open Call & New partnerships

include experimental & business development support



2

R&I agenda in key emerging technology platforms

Develop unique platforms to support multiple drug discovery programs



Multomics

(transcriptomics, proteomics, metabolomics)

Computational Chemistry & HTS

Organoids (kidney, heart, brain)



3

Training programs

Educate the next generation of sciencenpreneurs to lead new companies





Webinars,
Interaction with partners and society,
Design of academic programs

Training programs



Free webinars




Training programs



Free webinars

Post-graduation program

Training programs



Free webinars

Post-graduation program

Internships

Capabilities catalogue

exCell the patient mission

Co-Lab
AcceiBio



<https://www.linkedin.com/company/colab-accelbio/mycompany/>

